{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:59:59Z","timestamp":1785945599750,"version":"3.56.0"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000016","name":"U.S. Department of Health & Human Services","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NIH"},{"name":"National Cancer InstituteNational Cancer Institute (NCI)","award":["P30 CA023074"],"award-info":[{"award-number":["P30 CA023074"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.critrevonc.2019.02.011","type":"journal-article","created":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T12:26:03Z","timestamp":1551270363000},"page":"18-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Special considerations for the treatment of multiple myeloma according to advanced age, comorbidities, frailty and organ dysfunction"],"prefix":"10.1016","volume":"137","author":[{"given":"Muhammad Asad","family":"Fraz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiza Hassan","family":"Warraich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami Ullah","family":"Warraich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Junaid","family":"Tariq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zabih","family":"Warraich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Younas","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Usman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awais","family":"Ijaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavan","family":"Tenneti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeela","family":"Mushtaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Akbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaina","family":"Shahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeeshan","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafiz Muhammad","family":"Fazeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aboo","family":"Nasar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9430-4675","authenticated-orcid":false,"given":"Ali","family":"McBride","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiz","family":"Anwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.critrevonc.2019.02.011_bib0005","first-page":"34","article-title":"Clinical challenges: myeloma and concomitant type 2 diabetes","volume":"7","author":"Ahmed","year":"2013","journal-title":"Int. J.Hematol.-Oncol. Stem Cell Res."},{"issue":"8","key":"10.1016\/j.critrevonc.2019.02.011_bib0010","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1200\/JCO.2017.76.6402","article-title":"Role of bone-modifying agents in multiple myeloma: american society of clinical oncology clinical practice guideline update","volume":"36","author":"Anderson","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.02.011_bib0015","unstructured":"Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma [Available from: https:\/\/ClinicalTrials.gov\/show\/NCT02958969."},{"issue":"4","key":"10.1016\/j.critrevonc.2019.02.011_bib0020","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/bjh.13608","article-title":"Autologous haematopoietic cell transplantation in elderly patients with multiple myeloma","volume":"171","author":"Auner","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.critrevonc.2019.02.011_bib0025","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1365-2141.2008.07214.x","article-title":"Prevalence and significance of vitamin D deficiency in multiple myeloma patients","volume":"142","author":"Badros","year":"2008","journal-title":"Br. J. Haematol."},{"issue":"34","key":"10.1016\/j.critrevonc.2019.02.011_bib0030","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2019.02.011_bib0035","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3109\/10428194.2011.606942","article-title":"Feasibility of autologous hematopoietic stem cell transplant in patients aged &\/=70 years with multiple myeloma","volume":"53","author":"Bashir","year":"2012","journal-title":"Leuk. Lymphoma"},{"issue":"8","key":"10.1016\/j.critrevonc.2019.02.011_bib0040","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jacc.2013.05.064","article-title":"Prevalence and trends of Metabolic Syndrome in the adult US population, 1999\u20132010","volume":"62","author":"Beltr\u00e1n-S\u00e1nchez","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"issue":"10","key":"10.1016\/j.critrevonc.2019.02.011_bib0045","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2019.02.011_bib0050","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group","volume":"334","author":"Berenson","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.02.011_bib0055","series-title":"Mayo Consensus2012 April 20","author":"Bisphosphonates in Myeloma","year":"2018"},{"issue":"3","key":"10.1016\/j.critrevonc.2019.02.011_bib0060","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/cam4.620","article-title":"The outcomes of newly diagnosed elderly multiple myeloma patients treated at a single U.S. Institution","volume":"5","author":"Bonomo","year":"2016","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2019.02.011_bib0065","doi-asserted-by":"crossref","first-page":"12-","DOI":"10.1186\/1472-684X-8-12","article-title":"Balloon kyphoplasty in malignant spinal fractures: a systematic review and meta-analysis","volume":"8","author":"Bouza","year":"2009","journal-title":"BMC Palliat. Care"},{"issue":"6","key":"10.1016\/j.critrevonc.2019.02.011_bib0070","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3324\/haematol.2012.075051","article-title":"Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials","volume":"98","author":"Bringhen","year":"2013","journal-title":"Haematologica."},{"key":"10.1016\/j.critrevonc.2019.02.011_bib0075","series-title":"Mayo Consensus2012 April 17","author":"Calcium and Vitamin D Supplementation in Myeloma","year":"2018"},{"key":"10.1016\/j.critrevonc.2019.02.011_bib0080","series-title":"Cancer Stat Facts: Myeloma","author":"Cancer Stat Facts: Myeloma","year":"2018"},{"key":"10.1016\/j.critrevonc.2019.02.011_bib0085","series-title":"Cancer-Associated Venous Thromboembolic Disease Version 1.2018 April 20","author":"Cancer-Associated Venous Thromboembolic Disease","year":"2018"},{"issue":"3","key":"10.1016\/j.critrevonc.2019.02.011_bib0090","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1529-8027.2007.00141.x","article-title":"The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy\u2010induced peripheral neurotoxicity: Comparison with the National Cancer Institute\u2010Common Toxicity Scale","volume":"12","author":"Cavaletti","year":"2007","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"8 Suppl","key":"10.1016\/j.critrevonc.2019.02.011_bib0095","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer."},{"key":"10.1016\/j.critrevonc.2019.02.011_bib0100","doi-asserted-by":"crossref","DOI":"10.1102\/1470-7330.2005.0033","article-title":"Problems monitoring response in multiple myeloma","volume":"5","author":"Collins","year":"2005","journal-title":"Cancer Imaging"},{"issue":"11","key":"10.1016\/j.critrevonc.2019.02.011_bib0105","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1470-2045(10)70068-1","article-title":"Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues","volume":"11","author":"Delforge","year":"2010","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2019.02.011_bib0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2016.12.250","article-title":"Safety of high-dose melphalan (200\u2009Mg\/M2) as conditioning for autologous stem cell transplantation for myeloma in elderly patients","volume":"23","author":"Desai","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"7","key":"10.1016\/j.critrevonc.2019.02.011_bib0115","first-page":"968","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid","volume":"91","author":"Dimopoulos","year":"2006","journal-title":"Haematologica."},{"issue":"36","key":"10.1016\/j.critrevonc.2019.02.011_bib0120","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1200\/JCO.2009.22.2232","article-title":"VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study","volume":"27","author":"Dimopoulos","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"33","key":"10.1016\/j.critrevonc.2019.02.011_bib0125","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1200\/JCO.2010.30.8791","article-title":"Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group","volume":"28","author":"Dimopoulos","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2019.02.011_bib0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0609.2010.01432.x","article-title":"Lenalidomide and dexamethasone for the treatment of refractory\/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment","volume":"85","author":"Dimopoulos","year":"2010","journal-title":"Eur. J. Haematol."},{"issue":"13","key":"10.1016\/j.critrevonc.2019.02.011_bib0135","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","article-title":"International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment","volume":"34","author":"Dimopoulos","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2019.02.011_bib0140","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1182\/bloodadvances.2016003269","article-title":"Cardiac and renal complications of carfilzomib in patients with multiple myeloma","volume":"1","author":"Dimopoulos","year":"2017","journal-title":"Blood Adv."},{"issue":"4","key":"10.1016\/j.critrevonc.2019.02.011_bib0145","doi-asserted-by":"crossref","first-page":"516","DOI":"10.4065\/82.4.516","article-title":"Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement","volume":"82","author":"Durie","year":"2007","journal-title":"Mayo Clin. Proc."},{"issue":"8","key":"10.1016\/j.critrevonc.2019.02.011_bib0150","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.clml.2015.03.003","article-title":"Autologous hematopoietic stem cell transplantation in dialysis-dependent myeloma patients","volume":"15","author":"El Fakih","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"9","key":"10.1016\/j.critrevonc.2019.02.011_bib0155","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3324\/haematol.2016.148189","article-title":"Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores","volume":"101","author":"Engelhardt","year":"2016","journal-title":"Haematologica."},{"issue":"5","key":"10.1016\/j.critrevonc.2019.02.011_bib0160","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3324\/haematol.2016.162693","article-title":"A concise revised myeloma comorbidity index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients","volume":"102","author":"Engelhardt","year":"2017","journal-title":"Haematologica."},{"issue":"4","key":"10.1016\/j.critrevonc.2019.02.011_bib0165","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/j.1582-4934.2010.01083.x","article-title":"The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth","volume":"15","author":"Feng","year":"2011","journal-title":"J. Cell. Mol. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2019.02.011_bib0170","doi-asserted-by":"crossref","DOI":"10.1093\/gerona\/56.3.M146","article-title":"Frailty in older adults: evidence for a phenotype","volume":"56","author":"Fried","year":"2001","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"issue":"11","key":"10.1016\/j.critrevonc.2019.02.011_bib0175","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.3324\/haematol.2016.150334","article-title":"Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study","volume":"101","author":"Garderet","year":"2016","journal-title":"Haematologica."},{"issue":"2","key":"10.1016\/j.critrevonc.2019.02.011_bib0180","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/pbc.20620","article-title":"Treatment adherence and 6-mercaptopurine metabolites","volume":"46","author":"Gaynon","year":"2006","journal-title":"Pediatr. Blood Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2019.02.011_bib0185","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1002\/cam4.1128","article-title":"The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based study","volume":"6","author":"Gregersen","year":"2017","journal-title":"Cancer Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2019.02.011_bib0190","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1053\/j.ackd.2012.03.001","article-title":"Myeloma kidney: improving clinical outcomes?","volume":"19","author":"Haynes","year":"2012","journal-title":"Adv. Chronic Kidney Dis."},{"issue":"10","key":"10.1016\/j.critrevonc.2019.02.011_bib0195","first-page":"585","article-title":"Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies","volume":"22","author":"Jakubowiak","year":"2017","journal-title":"Hematology (Amsterdam, Netherlands)"},{"issue":"1","key":"10.1016\/j.critrevonc.2019.02.011_bib0200","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jobcr.2012.11.001","article-title":"Dental complications and management of patients on bisphosphonate therapy: a review article","volume":"3","author":"Kalra","year":"2013","journal-title":"J. Oral Biol. Craniofac. Res."},{"issue":"10","key":"10.1016\/j.critrevonc.2019.02.011_bib0205","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/qjmed\/hcm077","article-title":"Multiple myeloma: causes and consequences of delay in diagnosis","volume":"100","author":"Kariyawasan","year":"2007","journal-title":"QJM: Int. J. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2019.02.011_bib0210","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.bulcan.2016.01.020","article-title":"[Lenalidomide nephrotoxicity]","volume":"103","author":"Kheder El-Fekih","year":"2016","journal-title":"Bull. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2019.02.011_bib0215","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.clml.2016.11.009","article-title":"Incidence and risk of cardiac events in patients with previously treated multiple myeloma versus matched patients without multiple myeloma: an observational, retrospective, cohort study","volume":"17","author":"Kistler","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"6","key":"10.1016\/j.critrevonc.2019.02.011_bib0220","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1600-0609.2009.01318.x","article-title":"Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients","volume":"83","author":"Kleber","year":"2009","journal-title":"Eur. J. Haematol."},{"issue":"5","key":"10.1016\/j.critrevonc.2019.02.011_bib0225","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/joim.12299","article-title":"Obesity as a causal risk factor for deep venous thrombosis: a Mendelian randomization study","volume":"277","author":"Klovaite","year":"2015","journal-title":"J. Intern. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2019.02.011_bib0230","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1600-0609.1994.tb00190.x","article-title":"Renal function in newly diagnosed multiple myeloma--a demographic study of 1353 patients. The Nordic Myeloma Study Group","volume":"53","author":"Knudsen","year":"1994","journal-title":"Eur. J. Haematol."},{"issue":"9","key":"10.1016\/j.critrevonc.2019.02.011_bib0235","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1182\/blood-2008-04-151076","article-title":"Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma","volume":"112","author":"Kristinsson","year":"2008","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.critrevonc.2019.02.011_bib0240","first-page":"230","article-title":"Multiple myeloma, version 3.2017, NCCN clinical practice guidelines in oncology","volume":"15","author":"Kumar","year":"2017","journal-title":"J. Compr. Canc. Netw."},{"issue":"1","key":"10.1016\/j.critrevonc.2019.02.011_bib0245","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin. Proc."},{"issue":"8","key":"10.1016\/j.critrevonc.2019.02.011_bib0250","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4065\/81.8.1047","article-title":"Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma","volume":"81","author":"Lacy","year":"2006","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.critrevonc.2019.02.011_bib0255","series-title":"A Phase 2 Study of Three Low-dose Intensity Subcutaneous Bortezomib Regimens in Elderly Frail Patients with Untreated Multiple Myeloma","author":"Larocca","year":"2016"},{"key":"10.1016\/j.critrevonc.2019.02.011_bib0260","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-018-0142-9","article-title":"Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)","author":"Larocca","year":"2018","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.critrevonc.2019.02.011_bib0265","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/sj.bmt.1704440","article-title":"Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant","volume":"33","author":"Lee","year":"2004","journal-title":"Bone Marrow Transplant."},{"issue":"5","key":"10.1016\/j.critrevonc.2019.02.011_bib0270","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/leu.2013.293","article-title":"International Myeloma Working Group recommendations for global myeloma care","volume":"28","author":"Ludwig","year":"2014","journal-title":"Leukemia."},{"issue":"1","key":"10.1016\/j.critrevonc.2019.02.011_bib0275","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.bbmt.2017.08.028","article-title":"Adjuvant peptide pulsed dendritic cell vaccination in addition to t cell adoptive immunotherapy for cytomegalovirus infection in allogeneic hematopoietic stem cell transplantation recipients","volume":"24","author":"Ma","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.critrevonc.2019.02.011_bib0280","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2015-08-662627","article-title":"Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma","author":"Magarotto","year":"2016","journal-title":"Blood."},{"issue":"Suppl 3","key":"10.1016\/j.critrevonc.2019.02.011_bib0285","first-page":"4","article-title":"Peripheral neuropathy experience in patients with relapsed and\/or refractory multiple myeloma treated with carfilzomib","volume":"27","author":"Martin","year":"2013","journal-title":"Oncology (Williston Park, NY)"},{"key":"10.1016\/j.critrevonc.2019.02.011_bib0290","series-title":"Newly Diagnosed Myeloma 2016 4-19","author":"Mayo Stratification for Myeloma And Risk-adapted Therapy","year":"2018"},{"issue":"2","key":"10.1016\/j.critrevonc.2019.02.011_bib0295","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3324\/haematol.2017.174573","article-title":"From transplant to novel cellular therapies in multiple myeloma: european Myeloma Network guidelines and future perspectives","volume":"103","author":"Gay","year":"2018","journal-title":"Haematologica."},{"issue":"5","key":"10.1016\/j.critrevonc.2019.02.011_bib0300","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.clml.2016.01.008","article-title":"Management of carfilzomib-associated cardiac adverse events","volume":"16","author":"Mikhael","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"11","key":"10.1016\/j.critrevonc.2019.02.011_bib0305","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1080\/10428190802483778","article-title":"Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates","volume":"49","author":"Montefusco","year":"2008","journal-title":"Leuk. Lymphoma"},{"issue":"3","key":"10.1016\/j.critrevonc.2019.02.011_bib0310","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1600-0609.2009.01385.x","article-title":"Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA","volume":"84","author":"Morabito","year":"2010","journal-title":"Eur. J. Haematol."},{"issue":"5","key":"10.1016\/j.critrevonc.2019.02.011_bib0315","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol."},{"issue":"9757","key":"10.1016\/j.critrevonc.2019.02.011_bib0320","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet (London, England)"},{"issue":"8","key":"10.1016\/j.critrevonc.2019.02.011_bib0325","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(11)70157-7","article-title":"Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial","volume":"12","author":"Morgan","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.02.011_bib0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2018.02.008","article-title":"Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: a systematic review","volume":"125","author":"Mushtaq","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2019.02.011_bib0335","series-title":"National Diabetes Statistics Report","author":"National Diabetes Statistics Report","year":"2017"},{"key":"10.1016\/j.critrevonc.2019.02.011_bib0340","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.2147\/OTT.S49187","article-title":"An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma","volume":"7","author":"Offidani","year":"2014","journal-title":"OncoTargets Ther."},{"issue":"2","key":"10.1016\/j.critrevonc.2019.02.011_bib0345","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000357394","article-title":"Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network","volume":"132","author":"Ozaki","year":"2014","journal-title":"Acta Haematol."},{"issue":"34","key":"10.1016\/j.critrevonc.2019.02.011_bib0350","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial","volume":"28","author":"Palumbo","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2019.02.011_bib0355","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2011-06-358812","article-title":"Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)","volume":"118","author":"Palumbo","year":"2011","journal-title":"Blood."},{"issue":"10","key":"10.1016\/j.critrevonc.2019.02.011_bib0360","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2019.02.011_bib0365","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","article-title":"International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation","volume":"32","author":"Palumbo","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.critrevonc.2019.02.011_bib0370","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.critrevonc.2019.02.011_bib0375","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1212\/01.wnl.0000267271.18475.fe","article-title":"Neuropathy in multiple myeloma treated with thalidomide","volume":"69","author":"Plasmati","year":"2007","journal-title":"Neurology."},{"issue":"11","key":"10.1016\/j.critrevonc.2019.02.011_bib0380","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s00432-013-1513-2","article-title":"Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure","volume":"139","author":"Ponisch","year":"2013","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2019.02.011_bib0385","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2019.02.011_bib0390","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.bbmt.2015.05.013","article-title":"Cost-effectiveness of autologous hematopoietic stem cell transplantation for elderly patients with multiple myeloma using the surveillance, epidemiology, and end results-medicare database","volume":"21","author":"Shah","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"2","key":"10.1016\/j.critrevonc.2019.02.011_bib0395","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2019.02.011_bib0400","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.3324\/haematol.2016.151860","article-title":"Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial","volume":"101","author":"Straka","year":"2016","journal-title":"Haematologica."},{"issue":"16","key":"10.1016\/j.critrevonc.2019.02.011_bib0405","doi-asserted-by":"crossref","first-page":"E485","DOI":"10.1503\/cmaj.180115","article-title":"Warning of an increased risk of vertebral fracture after stopping denosumab","volume":"190","author":"Symonds","year":"2018","journal-title":"CMAJ : Can. Med. Assoc. J."},{"issue":"18","key":"10.1016\/j.critrevonc.2019.02.011_bib0410","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","article-title":"International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease","volume":"31","author":"Terpos","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2019.02.011_bib0415","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","article-title":"European Myeloma Network guidelines for the management of multiple myeloma-related complications","volume":"100","author":"Terpos","year":"2015","journal-title":"Haematologica."},{"key":"10.1016\/j.critrevonc.2019.02.011_bib0420","series-title":"CTCAE v3. 0: Development of a Comprehensive Grading System for the Adverse Effects of Cancer Treatment. Seminars in Radiation Oncology","year":"2003"},{"key":"10.1016\/j.critrevonc.2019.02.011_bib0425","doi-asserted-by":"crossref","first-page":"E65","DOI":"10.5888\/pcd10.120203","article-title":"Prevalence of multiple chronic conditions among US adults: estimates from the National Health Interview Survey, 2010","volume":"10","author":"Ward","year":"2013","journal-title":"Prev. Chronic Dis."},{"issue":"3","key":"10.1016\/j.critrevonc.2019.02.011_bib0430","doi-asserted-by":"crossref","first-page":"e174519","DOI":"10.1001\/jamaoncol.2017.4519","article-title":"Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis","volume":"4","author":"Waxman","year":"2018","journal-title":"JAMA Oncol."},{"issue":"21","key":"10.1016\/j.critrevonc.2019.02.011_bib0435","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.critrevonc.2019.02.011_bib0440","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1200\/JCO.2014.55.1028","article-title":"Multiple myeloma in the older adult: better prospects, more challenges","volume":"32","author":"Wildes","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2019.02.011_bib0445","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/bjc.2014.307","article-title":"The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma","volume":"111","author":"Wu","year":"2014","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2019.02.011_bib0450","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087671","article-title":"Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis","volume":"9","author":"Xiao","year":"2014","journal-title":"PLoS One"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842818303937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842818303937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:28:27Z","timestamp":1760902107000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842818303937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":90,"alternative-id":["S1040842818303937"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2019.02.011","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Special considerations for the treatment of multiple myeloma according to advanced age, comorbidities, frailty and organ dysfunction","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2019.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}